|
HU225496B1
(en)
|
1993-04-07 |
2007-01-29 |
Scios Inc |
Pharmaceutical compositions of prolonged delivery, containing peptides
|
|
US6284727B1
(en)
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
|
US5424286A
(en)
|
1993-05-24 |
1995-06-13 |
Eng; John |
Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
|
|
US5641757A
(en)
|
1994-12-21 |
1997-06-24 |
Ortho Pharmaceutical Corporation |
Stable 2-chloro-2'-deoxyadenosine formulations
|
|
JP2001501593A
(ja)
|
1996-08-08 |
2001-02-06 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
胃腸運動を調節するための方法
|
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
|
UA72181C2
(uk)
|
1996-08-30 |
2005-02-15 |
Ново Нордіск А/С |
Похідна глюкагоноподібного пептиду-1 (варіанти), фармацевтична композиція та спосіб одержання лікувального засобу (варіанти), спосіб лікування діабету (варіанти) і ожиріння
|
|
PT1629849E
(pt)
|
1997-01-07 |
2013-07-09 |
Amylin Pharmaceuticals Llc |
Composições farmacêuticas que compreendem exendinas e seus agonistas
|
|
US6410511B2
(en)
|
1997-01-08 |
2002-06-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US7312196B2
(en)
|
1997-01-08 |
2007-12-25 |
Amylin Pharmaceuticals, Inc. |
Formulations for amylin agonist peptides
|
|
US6723530B1
(en)
|
1997-02-05 |
2004-04-20 |
Amylin Pharmaceuticals, Inc. |
Polynucleotides encoding proexendin, and methods and uses thereof
|
|
NZ502592A
(en)
|
1997-08-08 |
2002-03-28 |
Amylin Pharmaceuticals Inc |
Exendin agonist peptides and their use in the treatment of type I and II diabetes
|
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
|
EP1032587B2
(en)
|
1997-11-14 |
2013-03-13 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
US7220721B1
(en)
|
1997-11-14 |
2007-05-22 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist peptides
|
|
AU757748B2
(en)
|
1997-11-14 |
2003-03-06 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
|
DK1044015T3
(da)
|
1998-01-09 |
2008-12-08 |
Amylin Pharmaceuticals Inc |
Formuleringer med amylinagonistpeptider og insulin
|
|
US6703359B1
(en)
|
1998-02-13 |
2004-03-09 |
Amylin Pharmaceuticals, Inc. |
Inotropic and diuretic effects of exendin and GLP-1
|
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
|
IL138214A0
(en)
|
1998-03-09 |
2001-10-31 |
Zealand Pharmaceuticals As |
Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
EP1061947B1
(en)
|
1998-03-13 |
2004-06-16 |
Novo Nordisk A/S |
Stabilized aqueous glucagon solutions comprising detergents
|
|
US6998387B1
(en)
|
1998-03-19 |
2006-02-14 |
Amylin Pharmaceuticals, Inc. |
Human appetite control by glucagon-like peptide receptor binding compounds
|
|
EA004538B1
(ru)
|
1998-06-12 |
2004-06-24 |
Амилин Фармасьютикалс, Инк. |
ГЛЮКАГОНОПОДОБНЫЙ ПЕПТИД-1, УЛУЧШАЮЩИЙ ОТВЕТ β-КЛЕТОК НА ГЛЮКОЗУ У СУБЪЕКТОВ С НАРУШЕНИЕМ ТОЛЕРАНТНОСТИ К ГЛЮКОЗЕ
|
|
ES2335066T3
(es)
|
1998-08-10 |
2010-03-18 |
The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Diferenciacion de celulas no productoras de insulina en celulas productoras de insulina glp-1 o exendina-4 y utilizaciones de las mismas.
|
|
JP2002524514A
(ja)
|
1998-09-17 |
2002-08-06 |
イーライ・リリー・アンド・カンパニー |
タンパク質製剤
|
|
US6284725B1
(en)
|
1998-10-08 |
2001-09-04 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
|
|
US6429197B1
(en)
|
1998-10-08 |
2002-08-06 |
Bionebraska, Inc. |
Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
|
|
US7259136B2
(en)
|
1999-04-30 |
2007-08-21 |
Amylin Pharmaceuticals, Inc. |
Compositions and methods for treating peripheral vascular disease
|
|
DE69928006T2
(de)
|
1998-12-22 |
2006-07-13 |
Eli Lilly And Co., Indianapolis |
Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
|
|
ES2343072T3
(es)
|
1999-01-14 |
2010-07-22 |
Amylin Pharmaceuticals, Inc. |
Exendina para la supresion del glucagon.
|
|
US6902744B1
(en)
|
1999-01-14 |
2005-06-07 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist formulations and methods of administration thereof
|
|
US20030087820A1
(en)
|
1999-01-14 |
2003-05-08 |
Young Andrew A. |
Novel exendin agonist formulations and methods of administration thereof
|
|
US7399489B2
(en)
|
1999-01-14 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Exendin analog formulations
|
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
|
AU3273500A
(en)
|
1999-03-17 |
2000-10-04 |
Novo Nordisk A/S |
Method for acylating peptides and novel acylating agents
|
|
NZ514916A
(en)
|
1999-04-30 |
2004-06-25 |
Amylin Pharmaceuticals Inc |
Exendins and exendin agonists linked to polyethylene glycol polymers
|
|
US6924264B1
(en)
|
1999-04-30 |
2005-08-02 |
Amylin Pharmaceuticals, Inc. |
Modified exendins and exendin agonists
|
|
DK1180121T3
(da)
|
1999-05-17 |
2004-03-01 |
Conjuchem Inc |
Langtidsvirkende insulinotrope peptider
|
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
|
US6849714B1
(en)
|
1999-05-17 |
2005-02-01 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US6887470B1
(en)
|
1999-09-10 |
2005-05-03 |
Conjuchem, Inc. |
Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
|
|
US6482799B1
(en)
|
1999-05-25 |
2002-11-19 |
The Regents Of The University Of California |
Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
|
|
US6506724B1
(en)
|
1999-06-01 |
2003-01-14 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
|
|
US6344180B1
(en)
|
1999-06-15 |
2002-02-05 |
Bionebraska, Inc. |
GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US6972319B1
(en)
|
1999-09-28 |
2005-12-06 |
Bayer Pharmaceuticals Corporation |
Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
|
|
GB9930882D0
(en)
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
|
WO2001051078A1
(en)
|
2000-01-10 |
2001-07-19 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
|
|
MXPA02009031A
(es)
|
2000-03-14 |
2004-08-19 |
Amylin Pharmaceuticals Inc |
Efectos del peptido-1(7-36) tipo glucagon en la motilidad antro-piloro.duodenal.
|
|
WO2001087322A2
(en)
|
2000-05-17 |
2001-11-22 |
Bionebraska, Inc. |
Peptide pharmaceutical formulations
|
|
AU6323001A
(en)
|
2000-05-19 |
2001-12-03 |
Bionebraska Inc |
Treatment of acute coronary syndrome with glp-1
|
|
EP1317412A1
(en)
|
2000-08-18 |
2003-06-11 |
Emisphere Technologies, Inc. |
Compounds and compositions for delivering active agents
|
|
US7507714B2
(en)
|
2000-09-27 |
2009-03-24 |
Bayer Corporation |
Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
|
|
DE60142351D1
(de)
|
2000-10-20 |
2010-07-22 |
Amylin Pharmaceuticals Inc |
Behandlung von hypoaktivem myokard und diabetischer herzmyopathie mit einem glp-1 peptid
|
|
AU2002226897B2
(en)
|
2000-12-07 |
2007-10-25 |
Eli Lilly And Company |
GLP-1 fusion proteins
|
|
WO2002047716A2
(en)
|
2000-12-13 |
2002-06-20 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
|
GB2371227A
(en)
|
2001-01-10 |
2002-07-24 |
Grandis Biotech Gmbh |
Crystallisation - resistant aqueous growth hormone formulations
|
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
|
AU2002308706A1
(en)
|
2001-06-01 |
2002-12-16 |
Eli Lilly And Company |
Glp-1 formulations with protracted time action
|
|
EP1412384B1
(en)
|
2001-06-28 |
2007-12-26 |
Novo Nordisk A/S |
Stable formulation of modified glp-1
|
|
CA2453434C
(en)
|
2001-07-16 |
2009-04-14 |
Hk Pharmaceuticals, Inc. |
Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
|
|
EP1411968B1
(en)
|
2001-07-31 |
2008-09-17 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Glp-1 exendin-4 peptide analogs and uses thereof
|
|
WO2003020201A2
(en)
|
2001-08-28 |
2003-03-13 |
Eli Lilly And Company |
Pre-mixes of glp-1 and basal insulin
|
|
JP2005508360A
(ja)
|
2001-10-19 |
2005-03-31 |
イーライ・リリー・アンド・カンパニー |
Ｇｌｐ−１およびインスリンの二相混合物
|
|
EP1997829A1
(en)
|
2001-12-21 |
2008-12-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
CA2484556A1
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US7105489B2
(en)
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
|
RU2332229C2
(ru)
|
2002-02-20 |
2008-08-27 |
Эмисфире Текнолоджис Инк. |
Способ введения молекул glp-1
|
|
DE60322513D1
(de)
|
2002-02-27 |
2008-09-11 |
Immunex Corp |
Stabilisierte TNFR-Fc Formulierung mit Arginin
|
|
ES2319634T3
(es)
|
2002-03-11 |
2009-05-11 |
Caprotec Bioanalytics Gmbh |
Compuestos y metodos para analizar el proteoma.
|
|
US7141240B2
(en)
|
2002-03-12 |
2006-11-28 |
Cedars-Sinai Medical Center |
Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
|
|
EP1494704A1
(en)
|
2002-04-04 |
2005-01-12 |
Novo Nordisk A/S |
Glp-1 agonist and cardiovascular complications
|
|
US20050164925A1
(en)
|
2002-04-10 |
2005-07-28 |
Joseph Anthony Jakubowski And Thurman Dwight Mc Kinney |
Treatment of gastroparesis
|
|
US6861236B2
(en)
|
2002-05-24 |
2005-03-01 |
Applied Nanosystems B.V. |
Export and modification of (poly)peptides in the lantibiotic way
|
|
US20040037826A1
(en)
|
2002-06-14 |
2004-02-26 |
Michelsen Birgitte Koch |
Combined use of a modulator of CD3 and a GLP-1 compound
|
|
AU2003232172A1
(en)
|
2002-06-14 |
2003-12-31 |
Novo Nordisk A/S |
Combined use of a modulator of cd3 and a glp-1 compound
|
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
|
MXPA04012497A
(es)
|
2002-07-04 |
2005-07-14 |
Zealand Pharma As |
Glp-1 y metodos para tratar la diabetes.
|
|
CA2491685A1
(en)
|
2002-07-09 |
2004-01-15 |
Sandoz Ag |
Liquid formulations with high concentration of human growth hormone (hgh) comprising 1,2-prolpylene glycol
|
|
US20070065469A1
(en)
|
2002-07-09 |
2007-03-22 |
Michael Betz |
Liquid formulations with high concentration of human growth hormone (high) comprising glycine
|
|
US20080260838A1
(en)
|
2003-08-01 |
2008-10-23 |
Mannkind Corporation |
Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
|
|
EP1545457A4
(en)
|
2002-08-01 |
2009-07-01 |
Mannkind Corp |
CELL TRANSPORT COMPOSITIONS AND ITS USES
|
|
US20040038865A1
(en)
|
2002-08-01 |
2004-02-26 |
Mannkind Corporation |
Cell transport compositions and uses thereof
|
|
CN100522962C
(zh)
|
2002-08-21 |
2009-08-05 |
贝林格尔英格海姆法玛两合公司 |
8-[3-氨基-哌啶-1-基]-黄嘌呤,其制备方法及作为药物制剂的用途
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
PL377591A1
(pl)
|
2002-10-02 |
2006-02-06 |
Zealand Pharma A/S |
Stabilizowane związki eksendyny-4
|
|
SI1583541T1
(sl)
|
2002-11-20 |
2011-08-31 |
Neuronova Ab |
Spojine in postopki za povečanje nevrogeneze
|
|
US20050209142A1
(en)
|
2002-11-20 |
2005-09-22 |
Goran Bertilsson |
Compounds and methods for increasing neurogenesis
|
|
US6969702B2
(en)
|
2002-11-20 |
2005-11-29 |
Neuronova Ab |
Compounds and methods for increasing neurogenesis
|
|
WO2004056313A2
(en)
|
2002-12-17 |
2004-07-08 |
Amylin Pharmaceuticals, Inc. |
Prevention and treatment of cardiac arrhythmias
|
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
|
US20040209803A1
(en)
|
2002-12-19 |
2004-10-21 |
Alain Baron |
Compositions for the treatment and prevention of nephropathy
|
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
|
CA2843439A1
(en)
|
2003-04-08 |
2004-10-21 |
Yeda Research And Development Co. Ltd |
Reversible pegylated drugs
|
|
WO2004089985A1
(en)
|
2003-04-11 |
2004-10-21 |
Novo Nordisk A/S |
Stable pharmaceutical compositions
|
|
AU2004240630B2
(en)
|
2003-05-15 |
2010-10-07 |
Trustees Of Tufts College |
Stable analogs of peptide and polypeptide therapeutics
|
|
US7947261B2
(en)
|
2003-05-23 |
2011-05-24 |
Nektar Therapeutics |
Conjugates formed from polymer derivatives having particular atom arrangements
|
|
JP5048332B2
(ja)
|
2003-05-23 |
2012-10-17 |
ネクター セラピューティクス |
特定の原子配置を有するポリマー誘導体
|
|
WO2005000222A2
(en)
|
2003-05-30 |
2005-01-06 |
Amylin Pharmaceuticals, Inc. |
Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
|
|
MXPA05013048A
(es)
|
2003-06-03 |
2006-03-02 |
Novo Nordisk As |
Composiciones peptodicas farmaceuticas estabilizadas.
|
|
BRPI0410972C1
(pt)
|
2003-06-03 |
2021-05-25 |
Novo Nordisk As |
método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
|
|
JP2007524592A
(ja)
|
2003-06-03 |
2007-08-30 |
ノボ・ノルデイスク・エー／エス |
安定化された薬学的ペプチド組成物
|
|
ES2375056T3
(es)
|
2003-06-03 |
2012-02-24 |
Novo Nordisk A/S |
Composiciones pept�?dicas farmacéuticas estabilizadas.
|
|
US8921311B2
(en)
|
2003-08-01 |
2014-12-30 |
Mannkind Corporation |
Method for treating hyperglycemia
|
|
AU2004261353B2
(en)
|
2003-08-05 |
2009-12-10 |
Novo Nordisk A/S |
Novel insulin derivatives
|
|
JP5622998B2
(ja)
|
2003-08-21 |
2014-11-12 |
ノヴォ ノルディスク アー／エス |
ラセミ化されたアミノ酸を含むポリペプチドの分離
|
|
US20060247167A1
(en)
|
2003-09-01 |
2006-11-02 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
WO2005021022A2
(en)
|
2003-09-01 |
2005-03-10 |
Novo Nordisk A/S |
Stable formulations of peptides
|
|
JP2007537981A
(ja)
|
2003-09-19 |
2007-12-27 |
ノボ ノルディスク アクティーゼルスカブ |
新規の血漿タンパク質親和性タグ
|
|
ES2373660T3
(es)
|
2003-11-13 |
2012-02-07 |
Novo Nordisk A/S |
Composición farmacéutica que comprende un análogo insulinotrópico de glp-1 (7-37), insulina asp(b28) y un tensioactivo.
|
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
|
US20050106214A1
(en)
|
2003-11-14 |
2005-05-19 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
US20050281879A1
(en)
|
2003-11-14 |
2005-12-22 |
Guohua Chen |
Excipients in drug delivery vehicles
|
|
EP1750752A2
(en)
|
2003-11-20 |
2007-02-14 |
Neuronova AB |
Compounds and methods for increasing neurogenesis
|
|
CN113304250A
(zh)
|
2003-11-20 |
2021-08-27 |
诺和诺德股份有限公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
|
ATE517119T1
(de)
|
2003-12-03 |
2011-08-15 |
Novo Nordisk As |
Einzelketteninsulin
|
|
CA2549011A1
(en)
|
2003-12-10 |
2005-06-30 |
Nektar Therapeutics Al, Corporation |
Compositions comprising two different populations of polymer-active agent conjugates
|
|
US20060210614A1
(en)
|
2003-12-26 |
2006-09-21 |
Nastech Pharmaceutical Company Inc. |
Method of treatment of a metabolic disease using intranasal administration of exendin peptide
|
|
WO2007065156A2
(en)
|
2005-12-02 |
2007-06-07 |
Nastech Pharmaceutical Company Inc. |
Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide
|
|
US20050143303A1
(en)
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
|
CN1938334A
(zh)
*
|
2004-01-30 |
2007-03-28 |
瓦拉塔药品公司 |
Glp－1激动剂和胃泌素化合物的联合使用
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
EP2335715A3
(en)
|
2004-02-11 |
2013-12-18 |
Amylin Pharmaceuticals, LLC |
Pancreatic polypeptide family motifs and polypeptides comprising the same
|
|
KR101427024B1
(ko)
|
2004-02-11 |
2014-08-05 |
아스트라제네카 파마수티컬스 엘피 |
선택가능한 특성을 갖는 하이브리드 폴리펩티드
|
|
WO2006083254A1
(en)
|
2004-02-11 |
2006-08-10 |
Amylin Pharmaceuticals, Inc. |
Amylin family peptides and methods for making and using them
|
|
US7399744B2
(en)
|
2004-03-04 |
2008-07-15 |
Amylin Pharmaceuticals, Inc. |
Methods for affecting body composition
|
|
US7456254B2
(en)
|
2004-04-15 |
2008-11-25 |
Alkermes, Inc. |
Polymer-based sustained release device
|
|
US20060110423A1
(en)
|
2004-04-15 |
2006-05-25 |
Wright Steven G |
Polymer-based sustained release device
|
|
DK1734971T3
(da)
|
2004-04-15 |
2012-02-13 |
Alkermes Pharma Ireland Ltd |
Indretning på polymerbasis med forsinket frigivelse
|
|
US20090069226A1
(en)
|
2004-05-28 |
2009-03-12 |
Amylin Pharmaceuticals, Inc. |
Transmucosal delivery of peptides and proteins
|
|
WO2005117584A2
(en)
|
2004-05-28 |
2005-12-15 |
Amylin Pharmaceuticals, Inc |
Improved transmucosal delivery of peptides and proteins
|
|
US8410047B2
(en)
|
2004-06-11 |
2013-04-02 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using GLP-1 agonists
|
|
ES2618028T3
(es)
|
2004-07-19 |
2017-06-20 |
Biocon Limited |
Conjugados insulina-oligómero, formulaciones y usos de éstos.
|
|
KR20070039593A
(ko)
|
2004-07-21 |
2007-04-12 |
암브룩스, 인코포레이티드 |
비천연적으로 코딩된 아미노산을 이용한 생합성 폴리펩티드
|
|
ZA200701484B
(en)
|
2004-08-03 |
2008-07-30 |
Biorexis Pharmaceutical Corp |
Combination therapy using transferrin fusion proteins comprising GLP-1
|
|
MX2007001877A
(es)
|
2004-08-16 |
2007-08-07 |
Water Un Ltd |
Aparato y metodo para enfriar aire.
|
|
WO2006024631A2
(en)
|
2004-08-31 |
2006-03-09 |
Novo Nordisk A/S |
Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
|
|
DE102004043153B4
(de)
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
TW200612991A
(en)
|
2004-09-07 |
2006-05-01 |
Chugai Pharmaceutical Co Ltd |
Process for producing water-soluble hyaluronic acid modification
|
|
WO2006029634A2
(en)
|
2004-09-17 |
2006-03-23 |
Novo Nordisk A/S |
Pharmaceutical compositions containing insulin and insulinotropic peptide
|
|
CA2582096C
(en)
|
2004-10-01 |
2014-01-07 |
Ramscor, Inc. |
Conveniently implantable sustained release drug compositions
|
|
EP1799711B1
(en)
|
2004-10-07 |
2012-06-20 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
|
US7595294B2
(en)
|
2004-10-08 |
2009-09-29 |
Transition Therapeutics, Inc. |
Vasoactive intestinal polypeptide pharmaceuticals
|
|
US20060089325A1
(en)
|
2004-10-13 |
2006-04-27 |
Sanjay Bhanot |
Antisense modulation of PTP1B expression
|
|
US7442682B2
(en)
|
2004-10-19 |
2008-10-28 |
Nitto Denko Corporation |
Transepithelial delivery of peptides with incretin hormone activities
|
|
ES2575984T3
(es)
|
2004-11-12 |
2016-07-04 |
Novo Nordisk A/S |
Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal
|
|
ES2735533T3
(es)
|
2004-11-12 |
2019-12-19 |
Novo Nordisk As |
Formulaciones estables de GLP-1
|
|
CN112618700A
(zh)
|
2004-11-12 |
2021-04-09 |
诺和诺德公司 |
促胰岛素肽的稳定制剂
|
|
RU2428431C2
(ru)
|
2004-12-02 |
2011-09-10 |
Домантис Лимитед |
Слитые конструкции лекарственного средства и конъюгаты
|
|
EP1824876B1
(en)
|
2004-12-13 |
2015-07-29 |
Amylin Pharmaceuticals, LLC |
Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
|
|
JP5243041B2
(ja)
|
2004-12-21 |
2013-07-24 |
ネクター セラピューティックス |
安定化ポリマーチオール試薬
|
|
AU2005319432A1
(en)
|
2004-12-22 |
2006-06-29 |
Eli Lilly And Company |
GLP-1 analog fusion protein formulations
|
|
EP1838336A2
(en)
|
2004-12-24 |
2007-10-03 |
Amylin Pharmaceuticals, Inc. |
Use of glp-1 and agonists thereof to prevent cardiac myocyte apoptosis
|
|
JP4785206B2
(ja)
|
2005-01-14 |
2011-10-05 |
ウクスィ・グランドチャンプ・ファーマシューティカル・テクノロジー・カンパニー・リミテッド |
修飾されたエキセンディン（Ｅｘｅｎｄｉｎｓ）及びその使用
|
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
|
EP1848541A4
(en)
|
2005-02-07 |
2013-01-16 |
Pharmalight Inc |
METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS
|
|
EP1853627A2
(en)
|
2005-02-11 |
2007-11-14 |
Amylin Pharmaceuticals, Inc. |
Gip analog and hybrid polypeptides with selectable properties
|
|
US20090286723A1
(en)
|
2005-02-11 |
2009-11-19 |
Amylin Pharmaceuticals, Inc. |
Hybrid Polypeptides with Selectable Properties
|
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
|
WO2006097535A2
(en)
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
|
US8946149B2
(en)
|
2005-04-11 |
2015-02-03 |
Amylin Pharmaceuticals, Llc |
Use of exendin and analogs thereof to delay or prevent cardiac remodeling
|
|
JP4979686B2
(ja)
|
2005-04-24 |
2012-07-18 |
ノボ・ノルデイスク・エー／エス |
注入デバイス
|
|
US8097584B2
(en)
|
2005-05-25 |
2012-01-17 |
Novo Nordisk A/S |
Stabilized formulations of insulin that comprise ethylenediamine
|
|
AR053495A1
(es)
|
2005-05-26 |
2007-05-09 |
Bristol Myers Squibb Co |
Moduladores del peptido 1 similar al glucagon humano y su uso en el tratamiento de la diabetes y condiciones relacionadas
|
|
CN101217940B
(zh)
|
2005-06-06 |
2013-03-27 |
卡穆鲁斯公司 |
Glp-1类似物制剂
|
|
GB0511986D0
(en)
|
2005-06-13 |
2005-07-20 |
Imp College Innovations Ltd |
Novel compounds and their effects on feeding behaviour
|
|
RU2485135C2
(ru)
|
2005-06-13 |
2013-06-20 |
Импиэриэл Инноувейшнс Лимитид |
Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
|
|
US8252275B2
(en)
|
2005-06-16 |
2012-08-28 |
Nektar Therapeutics |
Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
|
|
AU2006278490A1
(en)
|
2005-08-04 |
2007-02-15 |
Nektar Therapeutics |
Conjugates of a G-CSF moiety and a polymer
|
|
US8278420B2
(en)
|
2005-08-06 |
2012-10-02 |
Qinghua Wang |
Composition and method for prevention and treatment of type I diabetes
|
|
EP2347762B1
(en)
|
2005-08-19 |
2019-05-08 |
Amylin Pharmaceuticals, LLC |
Exendin for treating diabetes and reducing body weight
|
|
CN104324366B
(zh)
|
2005-09-14 |
2016-10-05 |
曼金德公司 |
以提高活性试剂对结晶微粒表面的亲和力为基础的药物配制方法
|
|
RU2440143C2
(ru)
|
2005-09-20 |
2012-01-20 |
Новартис Аг |
Применение ингибитора dpp-iv для снижения приступов гликемии
|
|
US8759290B2
(en)
|
2005-10-18 |
2014-06-24 |
Biocon Limited |
Oral glucagon-like peptide conjugates for metabolic diseases
|
|
US20070099820A1
(en)
|
2005-10-19 |
2007-05-03 |
Smartcells, Inc. |
Polymer-drug conjugates
|
|
EP2570133B1
(en)
|
2005-11-07 |
2016-03-23 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
|
US8039432B2
(en)
|
2005-11-09 |
2011-10-18 |
Conjuchem, Llc |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
|
|
US8293726B2
(en)
|
2005-12-02 |
2012-10-23 |
Vianova Labs, Inc. |
Treatment of cancer and other diseases
|
|
US20080318861A1
(en)
|
2005-12-08 |
2008-12-25 |
Nastech Pharmaceutical Company Inc. |
Mucosal Delivery of Stabilized Formulations of Exendin
|
|
WO2007075534A2
(en)
|
2005-12-16 |
2007-07-05 |
Nektar Therapeutics Al, Corporation |
Polymer conjugates of glp-1
|
|
CN101384272B
(zh)
|
2005-12-20 |
2013-05-01 |
杜克大学 |
用于递送具有增强的药理性质的活性剂的方法和组合物
|
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
|
SI1984009T1
(sl)
|
2006-01-18 |
2013-02-28 |
Qps, Llc |
Farmacevtski sestavki z izboljĺ ano stabilnostjo
|
|
AU2007212147A1
(en)
|
2006-02-03 |
2007-08-16 |
Medimmune, Llc |
Protein formulations
|
|
US7704953B2
(en)
|
2006-02-17 |
2010-04-27 |
Mdrna, Inc. |
Phage displayed cell binding peptides
|
|
WO2007109354A2
(en)
|
2006-03-21 |
2007-09-27 |
Amylin Pharmaceuticals, Inc. |
Peptide-peptidase inhibitor conjugates and methods of using same
|
|
CA2648440A1
(en)
|
2006-04-13 |
2007-10-25 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. . |
Pharmaceutical compositions of hglp-1, exendin-4 and analogs thereof
|
|
JP5415938B2
(ja)
|
2006-04-14 |
2014-02-12 |
マンカインド コーポレイション |
グルカゴン様ペプチド１（ｇｌｐ−１）医薬製剤
|
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
|
EP2029160A2
(en)
|
2006-05-12 |
2009-03-04 |
Amylin Pharmaceuticals, Inc. |
Methods to restore glycemic control
|
|
JP2009538356A
(ja)
|
2006-05-26 |
2009-11-05 |
アミリン・ファーマシューティカルズ，インコーポレイテッド |
鬱血性心不全の治療のための組成物および方法
|
|
WO2007139589A1
(en)
|
2006-05-26 |
2007-12-06 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
|
ES2401856T3
(es)
|
2006-06-21 |
2013-04-25 |
Biocon Limited |
Un método para producir un polipéptido biológicamente activo que tiene actividad insulinotrópica
|
|
SI2494959T1
(sl)
|
2006-07-05 |
2015-04-30 |
Foamix Pharmaceuticals Ltd. |
Penilno sredstvo dikarboksilne kisline in njega farmacevtski sestavki
|
|
WO2008012629A2
(en)
|
2006-07-24 |
2008-01-31 |
Biorexis Pharmaceutical Corporation |
Exendin fusion proteins
|
|
US7928186B2
(en)
|
2006-08-02 |
2011-04-19 |
Phoenix Pharmaceuticals, Inc. |
Cell permeable bioactive peptide conjugates
|
|
EP2046284A1
(en)
|
2006-08-04 |
2009-04-15 |
Nastech Pharmaceutical Company Inc. |
Compositions for intranasal delivery of human insulin and uses thereof
|
|
JP5048773B2
(ja)
|
2006-08-09 |
2012-10-17 |
インターシア セラピューティクス，インコーポレイティド |
浸透圧式デリバリーシステム及びピストンアセンブリー
|
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
|
CA2660835A1
(en)
|
2006-08-17 |
2008-02-21 |
Amylin Pharmaceuticals, Inc. |
Dpp-iv resistant gip hybrid polypeptides with selectable propperties
|
|
EP2057189B1
(en)
*
|
2006-08-25 |
2013-03-06 |
Novo Nordisk A/S |
Acylated exendin-4 compounds
|
|
CN101125207B
(zh)
|
2006-11-14 |
2012-09-05 |
上海华谊生物技术有限公司 |
带有聚乙二醇基团的艾塞丁或其类似物及其制剂和用途
|
|
CN101605530A
(zh)
|
2006-12-12 |
2009-12-16 |
安米林药品公司 |
药物制剂及其制备方法
|
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
|
SG177953A1
(en)
|
2007-01-05 |
2012-02-28 |
Univ Indiana Res & Tech Corp |
Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
|
|
CN101663317A
(zh)
*
|
2007-01-05 |
2010-03-03 |
CovX科技爱尔兰有限公司 |
胰高血糖素样蛋白-1受体glp-1r激动剂化合物
|
|
US20090098130A1
(en)
*
|
2007-01-05 |
2009-04-16 |
Bradshaw Curt W |
Glucagon-like protein-1 receptor (glp-1r) agonist compounds
|
|
RU2432361C2
(ru)
|
2007-01-05 |
2011-10-27 |
КовЭкс Текнолоджиз Айэлэнд Лимитед |
Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r)
|
|
WO2008098212A2
(en)
|
2007-02-08 |
2008-08-14 |
Diobex, Inc. |
Extended release formulations of glucagon and other peptides and proteins
|
|
EP2487184A1
(en)
|
2007-02-15 |
2012-08-15 |
Indiana University Research and Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
|
US8420598B2
(en)
|
2007-04-20 |
2013-04-16 |
B & L Delipharm Corp. |
Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
|
|
ES2402172T3
(es)
|
2007-04-23 |
2013-04-29 |
Intarcia Therapeutics, Inc |
Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
|
|
WO2008134425A1
(en)
|
2007-04-27 |
2008-11-06 |
Cedars-Sinai Medical Center |
Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
|
|
US7829664B2
(en)
|
2007-06-01 |
2010-11-09 |
Boehringer Ingelheim International Gmbh |
Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1), nucleic acid construct comprising same for production of glucagon-like peptide-1 (GLP-1), human cells comprising said construct and insulin-producing constructs, and methods of use thereof
|
|
CA2689909C
(en)
|
2007-06-08 |
2016-04-05 |
Ascendis Pharma As |
Long-acting polymeric prodrugs of exendin
|
|
WO2008152403A1
(en)
|
2007-06-15 |
2008-12-18 |
Zealand Pharma A/S |
Glucagon analogues
|
|
NZ582480A
(en)
|
2007-07-10 |
2011-03-31 |
Lilly Co Eli |
Glp-1-fc fusion protein formulation
|
|
EP2185178B1
(en)
|
2007-08-03 |
2017-08-23 |
Eli Lilly And Company |
Use of an fgf-21 compound and a glp-1 compound for the treatment of obesity
|
|
CN101366692A
(zh)
|
2007-08-15 |
2009-02-18 |
江苏豪森药业股份有限公司 |
一种稳定的艾塞那肽制剂
|
|
WO2009029847A1
(en)
|
2007-08-30 |
2009-03-05 |
Curedm, Inc. |
Compositions and methods of using proislet peptides and analogs thereof
|
|
US20100261637A1
(en)
|
2007-09-05 |
2010-10-14 |
Novo Nordisk A/S |
Peptides derivatized with a-b-c-d- and their therapeutical use
|
|
EP2200626A4
(en)
|
2007-09-07 |
2012-02-15 |
Ipsen Pharma Sas |
ANALOGUE OF EXENDIN-4 AND EXENDIN-3
|
|
HUE025485T2
(en)
|
2007-10-24 |
2016-02-29 |
Mannkind Corp |
Respiratory dry powder formulation containing GLP-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
|
|
MX2010004508A
(es)
|
2007-10-24 |
2010-07-02 |
Mannkind Corp |
Suministro de agentes activos.
|
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
|
EP2214691B1
(en)
|
2007-10-30 |
2015-09-30 |
Indiana University Research and Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
|
JP5669582B2
(ja)
|
2007-10-30 |
2015-02-12 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
グルカゴンアンタゴニスト
|
|
US8937042B2
(en)
|
2007-11-16 |
2015-01-20 |
Novo Nordisk A/S |
Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide
|
|
US8710002B2
(en)
|
2007-11-23 |
2014-04-29 |
Michael Rothkopf |
Methods of enhancing diabetes resolution
|
|
CN101444618B
(zh)
|
2007-11-26 |
2012-06-13 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
CN102026666B
(zh)
|
2007-12-11 |
2013-10-16 |
常山凯捷健生物药物研发（河北）有限公司 |
促胰岛素肽缀合物制剂
|
|
BRPI0907371A2
(pt)
|
2008-01-09 |
2015-11-24 |
Sanofi Aventis Deutschland |
derivados de insulina com um perfil de tempo-ação muito retardado
|
|
WO2009099763A1
(en)
|
2008-01-30 |
2009-08-13 |
Indiana University Research And Technology Corporation |
Ester-based peptide prodrugs
|
|
CN101980725B
(zh)
|
2008-02-01 |
2013-06-12 |
阿森迪斯药物股份有限公司 |
包含可自裂解的连接体的前药
|
|
RU2595380C2
(ru)
|
2008-02-06 |
2016-08-27 |
Байокон Лимитид |
Ферментационная среда для получения правастатина и способ получения правастатина
|
|
WO2009114959A1
(zh)
|
2008-03-20 |
2009-09-24 |
中国人民解放军军事医学科学院毒物药物研究所 |
可注射用缓释药物制剂及其制备方法
|
|
EP2282763B1
(en)
|
2008-04-07 |
2013-12-11 |
National Institute Of Immunology |
Process for preparing supramolecular calcitonin assemblies (SCA)
|
|
WO2009137078A1
(en)
|
2008-05-07 |
2009-11-12 |
Merrion Research Iii Limited |
Compositions of peptides and processes of preparation thereof
|
|
ES2552646T3
(es)
|
2008-05-21 |
2015-12-01 |
Amylin Pharmaceuticals, Inc. |
Exendinas para disminuir el colesterol y los triglicéridos
|
|
WO2009143014A1
(en)
|
2008-05-23 |
2009-11-26 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist bioassays
|
|
US9358352B2
(en)
|
2008-06-13 |
2016-06-07 |
Mannkind Corporation |
Dry powder drug delivery system and methods
|
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
|
EP2293833B1
(en)
|
2008-06-13 |
2016-02-17 |
MannKind Corporation |
A dry powder inhaler and system for drug delivery
|
|
AR072160A1
(es)
|
2008-06-17 |
2010-08-11 |
Univ Indiana Res & Tech Corp |
Co-agonistas del receptor de glucagon/glp-1
|
|
JP5753779B2
(ja)
|
2008-06-17 |
2015-07-22 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ |
生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
|
|
WO2009153960A1
(ja)
|
2008-06-17 |
2009-12-23 |
大塚化学株式会社 |
糖鎖付加ｇｌｐ－１ペプチド
|
|
EP2952202B1
(en)
|
2008-06-17 |
2017-10-18 |
Indiana University Research and Technology Corporation |
Gip-based mixed agonists for treatment of metabolic disorders and obesity
|
|
EP2926825A1
(en)
|
2008-06-27 |
2015-10-07 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
|
US20110129522A1
(en)
|
2008-07-21 |
2011-06-02 |
Transpharma Medical Ltd. |
Transdermal system for extended delivery of incretins and incretn mimetic peptides
|
|
WO2010013012A2
(en)
|
2008-08-01 |
2010-02-04 |
Lund University Bioscience Ab |
Novel polypeptides and uses thereof
|
|
CN101670096B
(zh)
|
2008-09-11 |
2013-01-16 |
杭州九源基因工程有限公司 |
含有艾塞那肽的药物制剂
|
|
KR101820024B1
(ko)
|
2008-10-17 |
2018-01-18 |
사노피-아벤티스 도이칠란트 게엠베하 |
인슐린과 ｇｌｐ－1 효능제의 병용물
|
|
JP2012511586A
(ja)
|
2008-12-10 |
2012-05-24 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
医薬組成物
|
|
US8680049B2
(en)
|
2008-12-15 |
2014-03-25 |
Zealand Pharma A/S |
Glucagon analogues
|
|
MX2011006320A
(es)
|
2008-12-15 |
2011-09-22 |
Zealand Pharma As |
Analogos de glucagon.
|
|
CN102292347A
(zh)
|
2008-12-15 |
2011-12-21 |
西兰制药公司 |
胰高血糖素类似物
|
|
WO2010070251A1
(en)
|
2008-12-15 |
2010-06-24 |
Zealand Pharma A/S |
Glucagon analogues
|
|
SG172291A1
(en)
|
2008-12-19 |
2011-07-28 |
Univ Indiana Res & Tech Corp |
Amide based glucagon superfamily peptide prodrugs
|
|
CN101538323B
(zh)
|
2009-01-13 |
2012-05-09 |
深圳翰宇药业股份有限公司 |
一种纯化艾塞那肽的方法
|
|
DE102009006602A1
(de)
|
2009-01-29 |
2010-08-05 |
Bayer Schering Pharma Aktiengesellschaft |
Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
|
|
WO2010096052A1
(en)
|
2009-02-19 |
2010-08-26 |
Merck Sharp & Dohme Corp. |
Oxyntomodulin analogs
|
|
RU2487731C2
(ru)
|
2009-03-04 |
2013-07-20 |
Маннкайнд Корпорейшн |
Усовершенствованная система доставки сухого порошкообразного лекарственного средства
|
|
EP2403569B1
(en)
|
2009-03-05 |
2014-04-23 |
Sanofi-Aventis Deutschland GmbH |
Drug delivery device with retractable needle
|
|
US8642544B2
(en)
|
2009-04-01 |
2014-02-04 |
Amylin Pharmaceuticals, Llc |
N-terminus conformationally constrained GLP-1 receptor agonist compounds
|
|
US8992886B2
(en)
|
2009-04-06 |
2015-03-31 |
Board Of Regents, The University Of Texas System |
Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
|
|
US9012606B2
(en)
|
2009-04-22 |
2015-04-21 |
Alteogen, Inc. |
In vivo half life increased fusion protein or peptide maintained by sustained in vivo release, and method for increasng in vivo half-life using same
|
|
CN101870728A
(zh)
|
2009-04-23 |
2010-10-27 |
派格生物医药(苏州)有限公司 |
新型Exendin变体及其缀合物
|
|
CN101559041B
(zh)
|
2009-05-19 |
2014-01-15 |
中国科学院过程工程研究所 |
粒径均一的多肽药物缓释微球或微囊制剂及制备方法
|
|
EP3189868B1
(en)
|
2009-05-20 |
2024-10-23 |
Sanofi-Aventis Deutschland GmbH |
A bung for drug containing cartridges in drug delivery devices comprising an electronic coding feature
|
|
WO2010133675A1
(en)
|
2009-05-20 |
2010-11-25 |
Sanofi-Aventis Deutschland Gmbh |
A bung for drug containing cartridges in drug delivery devices
|
|
US20120231022A1
(en)
|
2009-05-28 |
2012-09-13 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonist compounds for sleep enhancement
|
|
WO2010142665A1
(en)
|
2009-06-11 |
2010-12-16 |
Novo Nordisk A/S |
Glp-1 and fgf21 combinations for treatment of diabetes type 2
|
|
CN102459325B
(zh)
|
2009-06-16 |
2015-03-25 |
印第安纳大学科技研究有限公司 |
胃抑胜肽受体活化的胰高血糖素化合物
|
|
AU2010268726A1
(en)
|
2009-07-02 |
2012-01-19 |
Angiochem Inc. |
Multimeric peptide conjugates and uses thereof
|
|
SI2454282T1
(sl)
|
2009-07-13 |
2015-06-30 |
Zealand Pharma A/S |
Acilirani glukagonski analogi
|
|
CN101601646B
(zh)
|
2009-07-22 |
2011-03-23 |
南京凯瑞尔纳米生物技术有限公司 |
治疗糖尿病的鼻腔滴剂及其制备方法
|
|
WO2011011675A1
(en)
|
2009-07-23 |
2011-01-27 |
Zelos Therapeutics, Inc. |
Pharmaceutically acceptable formulations/compositions for peptidyl drugs
|
|
MX2012001399A
(es)
|
2009-07-31 |
2012-03-21 |
Sanofi Aventis Deutschland |
Profarmacos que comprenden un conjugado de insulina-conector.
|
|
WO2011017835A1
(en)
|
2009-08-11 |
2011-02-17 |
Nanjing University |
Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
|
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
|
US20120148586A1
(en)
|
2009-08-27 |
2012-06-14 |
Joyce Ching Tsu Chou |
Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
|
|
SG10201406063XA
(en)
|
2009-09-30 |
2014-11-27 |
Glaxo Group Ltd |
Drug fusions and conjugates with extended half life
|
|
EP2490708B1
(en)
|
2009-10-22 |
2013-03-27 |
Biodel Inc. |
Stabilized glucagon solutions
|
|
US9610329B2
(en)
|
2009-10-22 |
2017-04-04 |
Albireo Pharma, Inc. |
Stabilized glucagon solutions
|
|
US20110097386A1
(en)
|
2009-10-22 |
2011-04-28 |
Biodel, Inc. |
Stabilized glucagon solutions
|
|
KR20120101037A
(ko)
|
2009-10-30 |
2012-09-12 |
오츠카 가가쿠 가부시키가이샤 |
항원성 ｇｌｐ?１ 아날로그의 당쇄 부가체
|
|
NZ599945A
(en)
|
2009-11-02 |
2014-05-30 |
Pfizer |
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
|
|
US20120294855A1
(en)
|
2009-11-03 |
2012-11-22 |
Eli Lilly & Company |
Glp-1 receptor agonist compounds for obstructive sleep apnea
|
|
EP3831402A1
(de)
|
2009-11-13 |
2021-06-09 |
Sanofi-Aventis Deutschland GmbH |
Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten, ein insulin und methionin
|
|
MX2012005184A
(es)
|
2009-11-13 |
2012-06-08 |
Sanofi Aventis Deutschland |
Composicion farmaceutica que comprende un agonista de glp-1 y metionina.
|
|
DK2512470T3
(en)
|
2009-12-15 |
2017-02-27 |
Octeta Therapeutics Llc |
PPAR SAVING THIAZOLIDE INDIA AND COMBINATIONS TO TREAT NEURODEGENERATIVE DISEASES
|
|
RU2564661C2
(ru)
|
2009-12-15 |
2015-10-10 |
МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи |
Соли тиазолидиндиона со сниженным сродством к ppar для лечения нарушений обмена веществ
|
|
KR20120092712A
(ko)
|
2009-12-15 |
2012-08-21 |
메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 |
진성 당뇨병 및 다른 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
|
|
KR20120092714A
(ko)
|
2009-12-15 |
2012-08-21 |
메타볼릭 솔루션스 디벨롭먼트 컴퍼니, 엘엘씨 |
비만 및 다른 대사성 질환의 치료를 위한 ｐｐａｒ 절약형 티아졸리딘디온 및 복합제
|
|
TWI484974B
(zh)
|
2009-12-16 |
2015-05-21 |
Novo Nordisk As |
雙重醯化ｇｌｐ－１衍生物
|
|
CN102933200B
(zh)
|
2009-12-18 |
2015-11-25 |
莱迪杜德制药公司 |
包含磷脂的单相凝胶组合物
|
|
EP2512503A4
(en)
|
2009-12-18 |
2013-08-21 |
Univ Indiana Res & Tech Corp |
COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
|
|
CN101798588B
(zh)
*
|
2009-12-21 |
2015-09-09 |
上海仁会生物制药股份有限公司 |
Glp-1受体激动剂生物学活性测定方法
|
|
JO2976B1
(en)
|
2009-12-22 |
2016-03-15 |
ايلي ليلي اند كومباني |
Axentomodulin polypeptide
|
|
AR079344A1
(es)
|
2009-12-22 |
2012-01-18 |
Lilly Co Eli |
Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
|
|
CA2786934A1
(en)
|
2010-01-20 |
2011-07-28 |
Zealand Pharma A/S |
Treatment of cardiac conditions
|
|
JP2013518115A
(ja)
|
2010-01-27 |
2013-05-20 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
|
|
CN104474610B
(zh)
|
2010-02-01 |
2018-09-14 |
赛诺菲-安万特德国有限公司 |
药筒保持器、给药装置和用于将药筒固定在药筒保持器中的方法
|
|
WO2011109784A1
(en)
|
2010-03-05 |
2011-09-09 |
Conjuchem, Llc |
Formulation of insulinotropic peptide conjugates
|
|
CA2793737A1
(en)
|
2010-03-24 |
2011-09-29 |
Shifamed Holdings, Llc |
Intravascular tissue disruption
|
|
AR080592A1
(es)
*
|
2010-03-26 |
2012-04-18 |
Lilly Co Eli |
Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
|
|
US20130143798A1
(en)
|
2010-03-26 |
2013-06-06 |
Novo Nordisk A/S |
Novel glucagon analogues
|
|
JP6050746B2
(ja)
|
2010-05-13 |
2016-12-21 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
|
|
MX2012013001A
(es)
|
2010-05-13 |
2013-02-26 |
Univ Indiana Res & Tech Corp |
Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
AU2011254559B2
(en)
|
2010-05-20 |
2014-09-04 |
Glaxo Group Limited |
Improved anti-serum albumin binding variants
|
|
WO2011156407A2
(en)
|
2010-06-09 |
2011-12-15 |
Amylin Pharmaceuticals, Inc. |
Glp-1 receptor agonists to treat pancre-atitis
|
|
CN101891823B
(zh)
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
|
US8636711B2
(en)
|
2010-06-14 |
2014-01-28 |
Legacy Emanuel Hospital & Health Center |
Stabilized glucagon solutions and uses therefor
|
|
AR081975A1
(es)
|
2010-06-23 |
2012-10-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
US9234023B2
(en)
|
2010-06-24 |
2016-01-12 |
Biousian Biosystems, Inc. |
Glucagon-like peptide-1 glycopeptides
|
|
MX2012014576A
(es)
|
2010-06-24 |
2013-02-21 |
Univ Indiana Res & Tech Corp |
Profarmacos de peptido de la superfamilia de glucagon basado en amida.
|
|
WO2011163473A1
(en)
|
2010-06-25 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
|
|
US20130137645A1
(en)
|
2010-07-19 |
2013-05-30 |
Mary S. Rosendahl |
Modified peptides and proteins
|
|
WO2012012460A1
(en)
|
2010-07-19 |
2012-01-26 |
Xeris Pharmaceuticals, Inc. |
Stable glucagon formulations for the treatment of hypoglycemia
|
|
EA201390182A1
(ru)
|
2010-07-28 |
2014-01-30 |
АМИЛИН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Соединения-агонисты рецептора glp-1, содержащие стабилизированные области
|
|
CN102397558B
(zh)
|
2010-09-09 |
2013-08-14 |
中国人民解放军军事医学科学院毒物药物研究所 |
Exendin-4类似物的定位聚乙二醇化修饰物及其用途
|
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
|
CA2812951A1
(en)
|
2010-09-28 |
2012-04-19 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides having enhanced duration of action
|
|
EP2635296B1
(en)
|
2010-11-03 |
2014-12-24 |
Arecor Limited |
Novel composition comprising glucagon
|
|
WO2012064892A1
(en)
|
2010-11-09 |
2012-05-18 |
Mannkind Corporation |
Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
|
|
EP2460552A1
(en)
|
2010-12-06 |
2012-06-06 |
Sanofi-Aventis Deutschland GmbH |
Drug delivery device with locking arrangement for dose button
|
|
CN102552883B
(zh)
|
2010-12-09 |
2014-02-19 |
天津药物研究院 |
一种多肽复合物、药物组合物、其制备方法和应用
|
|
CA2821886A1
(en)
|
2010-12-16 |
2012-06-21 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
|
US8507428B2
(en)
|
2010-12-22 |
2013-08-13 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting GIP receptor activity
|
|
EP2654767A4
(en)
|
2010-12-22 |
2014-05-21 |
Amylin Pharmaceuticals Inc |
GLP-1 RECEPTOR AGONISTS FOR ISLAND CELL TRANSPLANTATION
|
|
CN102532301B
(zh)
|
2010-12-31 |
2014-09-03 |
上海医药工业研究院 |
一类新型的Exendin-4类似物及其制备方法
|
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
CN102100906A
(zh)
|
2011-02-18 |
2011-06-22 |
深圳翰宇药业股份有限公司 |
一种艾塞那肽的药用制剂及其制备方法
|
|
US8697644B2
(en)
|
2011-03-10 |
2014-04-15 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of peptide drugs
|
|
CN102718858B
(zh)
|
2011-03-29 |
2014-07-02 |
天津药物研究院 |
胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用
|
|
CN102718868A
(zh)
|
2011-03-30 |
2012-10-10 |
上海华谊生物技术有限公司 |
定点单取代聚乙二醇化Exendin类似物及其制备方法
|
|
DK2694095T3
(en)
|
2011-04-05 |
2018-05-28 |
Longevity Biotech Inc |
COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
|
|
WO2012140647A2
(en)
|
2011-04-11 |
2012-10-18 |
Yeda Research And Development Co. Ltd |
Albumin binding probes and drug conjugates thereof
|
|
WO2012150503A2
(en)
|
2011-05-03 |
2012-11-08 |
Zealand Pharma A/S |
Glu-glp-1 dual agonist signaling-selective compounds
|
|
CN102766204B
(zh)
|
2011-05-05 |
2014-10-15 |
天津药物研究院 |
胰高血糖素样肽-1突变体多肽及其制备方法和其应用
|
|
CN103732617A
(zh)
|
2011-05-18 |
2014-04-16 |
梅德瑞斯糖尿病有限责任公司 |
用于胰岛素抵抗的改进的肽医药
|
|
EP2714069A4
(en)
|
2011-05-25 |
2015-06-24 |
Amylin Pharmaceuticals Llc |
LONG-TERM CONJUGATES WITH TWO HORMONES
|
|
UA113626C2
(xx)
|
2011-06-02 |
2017-02-27 |
|
Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
|
|
WO2012169798A2
(en)
|
2011-06-10 |
2012-12-13 |
Hanmi Science Co., Ltd. |
Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
|
|
US9453062B2
(en)
|
2011-06-10 |
2016-09-27 |
Beijing Hanmi Pharmaceutical Co., Ltd. |
Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
|
|
PE20141178A1
(es)
|
2011-06-17 |
2014-09-12 |
Hanmi Science Co Ltd |
Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
|
|
ES2566549T3
(es)
|
2011-06-17 |
2016-04-13 |
Halozyme, Inc. |
Formulaciones estables de enzima degradante de hialuronano
|
|
US9156902B2
(en)
|
2011-06-22 |
2015-10-13 |
Indiana University Research And Technology Corporation |
Glucagon/GLP-1 receptor co-agonists
|
|
RU2014101697A
(ru)
|
2011-06-22 |
2015-07-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Коагонисты рецепторов глюкагона/glp-1
|
|
US20140220134A1
(en)
|
2011-06-24 |
2014-08-07 |
Astrazeneca Pharamceuticals LP |
Method for treating diabetes with extended release formulation of glp-1 receptor agonists
|
|
KR101357117B1
(ko)
|
2011-06-28 |
2014-02-06 |
비앤엘델리팜 주식회사 |
폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
|
|
EP2729493B1
(en)
|
2011-07-04 |
2020-06-10 |
IP2IPO Innovations Limited |
Novel compounds and their effects on feeding behaviour
|
|
JP6006309B2
(ja)
|
2011-07-08 |
2016-10-12 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
|
|
RU2578460C2
(ru)
|
2011-08-10 |
2016-03-27 |
Адосиа |
Приемлемый для инъекций раствор по меньшей мере одного базального инсулина
|
|
JP6169079B2
(ja)
|
2011-08-24 |
2017-07-26 |
フェーズバイオ ファーマシューティカルズ，インコーポレイテッド |
徐放のための活性剤の製剤
|
|
CN103189389B
(zh)
|
2011-09-03 |
2017-08-11 |
深圳市健元医药科技有限公司 |
新的glp‑ⅰ类似物及其制备方法和用途
|
|
CN104093735B
(zh)
|
2011-09-23 |
2018-07-06 |
诺沃—诺迪斯克有限公司 |
新的胰高血糖素类似物
|
|
SG11201401175SA
(en)
|
2011-10-28 |
2014-09-26 |
Sanofi Aventis Deutschland |
Treatment protocol of diabetes type 2
|
|
CN102363633B
(zh)
|
2011-11-16 |
2013-11-20 |
天津拓飞生物科技有限公司 |
胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用
|
|
EP2780031B1
(en)
|
2011-11-17 |
2018-03-07 |
Indiana University Research and Technology Corporation |
Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
|
|
DK2785352T3
(da)
|
2011-11-29 |
2020-05-25 |
Jurox Pty Ltd |
Stabile injicerbare farmaceutiske sammensætninger omfattende 2-hydroxypropyl-beta-cyclodextrin og alfaxalon
|
|
RU2649364C2
(ru)
|
2011-12-16 |
2018-04-02 |
Модерна Терапьютикс, Инк. |
Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты
|
|
CN104066438B
(zh)
|
2011-12-22 |
2015-09-23 |
辉瑞公司 |
抗糖尿病化合物
|
|
KR20140114845A
(ko)
|
2011-12-23 |
2014-09-29 |
질랜드 파마 에이/에스 |
글루카곤 유사체
|
|
EP2797585A4
(en)
|
2011-12-29 |
2015-10-07 |
Latitude Pharmaceuticals Inc |
STABILIZED GLUCAGONNANOULULSIONS
|
|
US9198971B2
(en)
|
2012-01-09 |
2015-12-01 |
Adocia |
Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
|
|
EP2844269A4
(en)
|
2012-03-28 |
2016-01-06 |
Amylin Pharmaceuticals Llc |
TRANSMUCULOUS ADMINISTRATION OF GENETICALLY MODIFIED POLYPEPTIDES
|
|
WO2013148871A1
(en)
|
2012-03-28 |
2013-10-03 |
Amylin Pharmaceuticals, Llc |
Engineered polypeptides
|
|
WO2013151671A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
JP2015518705A
(ja)
|
2012-04-02 |
2015-07-06 |
モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド
|
|
CN102649947A
(zh)
|
2012-04-20 |
2012-08-29 |
无锡和邦生物科技有限公司 |
一种用于测定glp-1及其功能类似物生物活性的细胞株及其应用
|
|
US20150111246A1
(en)
|
2012-04-24 |
2015-04-23 |
Astrazeneca Pharmaceuticals Lp |
Site-specific enzymatic modification of exendins and analogs thereof
|
|
US20130289241A1
(en)
|
2012-04-26 |
2013-10-31 |
Shanghai Ambiopharm, Inc. |
Method for preparing exenatide
|
|
US8901484B2
(en)
|
2012-04-27 |
2014-12-02 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
WO2013182217A1
(en)
|
2012-04-27 |
2013-12-12 |
Sanofi-Aventis Deutschland Gmbh |
Quantification of impurities for release testing of peptide products
|
|
CN104470948B
(zh)
|
2012-05-03 |
2018-06-15 |
西兰制药公司 |
Gip-glp-1双激动剂化合物及方法
|
|
US9453064B2
(en)
|
2012-05-03 |
2016-09-27 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (GLP-2) analogues
|
|
EP2664374A1
(en)
|
2012-05-15 |
2013-11-20 |
F. Hoffmann-La Roche AG |
Lysin-glutamic acid dipeptide derivatives
|
|
CN103421094A
(zh)
|
2012-05-24 |
2013-12-04 |
上海医药工业研究院 |
一种具有epo类似活性的多肽化合物
|
|
WO2013177565A1
(en)
|
2012-05-25 |
2013-11-28 |
Amylin Pharmaceuticals, Llc |
Insulin-pramlintide compositions and methods for making and using them
|
|
CA2875743A1
(en)
|
2012-06-14 |
2013-12-19 |
Sanofi |
Exendin-4 peptide analogues
|
|
RU2015101697A
(ru)
|
2012-06-21 |
2016-08-10 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Аналоги глюкагона, обладающие активностью рецептора gip
|
|
US9868772B2
(en)
|
2012-06-21 |
2018-01-16 |
Indiana University Research And Technology Corporation |
Analogs of glucagon exhibiting GIP receptor activity
|
|
CA2878457C
(en)
|
2012-07-12 |
2021-01-19 |
Mannkind Corporation |
Dry powder drug delivery systems and methods
|
|
CA2878991C
(en)
|
2012-07-23 |
2021-12-07 |
Zealand Pharma A/S |
Glucagon analogues
|
|
KR101968344B1
(ko)
|
2012-07-25 |
2019-04-12 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
|
|
AR092862A1
(es)
|
2012-07-25 |
2015-05-06 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
|
|
AR094821A1
(es)
|
2012-07-25 |
2015-09-02 |
Hanmi Pharm Ind Co Ltd |
Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
|
|
US20150224176A1
(en)
|
2012-08-14 |
2015-08-13 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
WO2014027254A1
(en)
|
2012-08-14 |
2014-02-20 |
Wockhardt Limited |
Pharmaceutical microparticulate compositions of polypeptides
|
|
CN102816244A
(zh)
|
2012-08-23 |
2012-12-12 |
无锡和邦生物科技有限公司 |
一种Exendin-4肽与人血清白蛋白HSA的融合蛋白及其制备方法
|
|
CN102827270A
(zh)
|
2012-09-13 |
2012-12-19 |
无锡和邦生物科技有限公司 |
一种聚乙二醇化艾塞那肽衍生物及其用途
|
|
US9546205B2
(en)
|
2012-09-17 |
2017-01-17 |
Imperial Innovations Limited |
Peptide analogues of glucagon and GLP1
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
AR092873A1
(es)
|
2012-09-26 |
2015-05-06 |
Cadila Healthcare Ltd |
Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
KR101993393B1
(ko)
|
2012-11-06 |
2019-10-01 |
한미약품 주식회사 |
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
|
|
EP2916819B1
(en)
|
2012-11-06 |
2019-07-10 |
Hanmi Pharm. Co., Ltd. |
Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
|
|
JP6525456B2
(ja)
|
2012-11-20 |
2019-06-05 |
メデリス ダイアビーティーズ，エルエルシー |
インスリン抵抗性のための改善されたペプチド製剤
|
|
TWI674270B
(zh)
|
2012-12-11 |
2019-10-11 |
英商梅迪繆思有限公司 |
用於治療肥胖之升糖素與glp-1共促效劑
|
|
ES2688367T3
(es)
*
|
2012-12-21 |
2018-11-02 |
Sanofi |
Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón
|
|
CN103908657A
(zh)
|
2012-12-31 |
2014-07-09 |
复旦大学附属华山医院 |
胰升糖素样肽-1类似物在制备眼科疾病药物中的用途
|
|
KR20150131213A
(ko)
|
2013-03-14 |
2015-11-24 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
인슐린-인크레틴 접합체들
|
|
WO2014140222A1
(en)
|
2013-03-14 |
2014-09-18 |
Medimmune Limited |
Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
|
|
US20160058881A1
(en)
|
2013-03-15 |
2016-03-03 |
Indiana University Research And Technology Corporation |
Prodrugs with prolonged action
|
|
PL2986313T3
(pl)
|
2013-04-18 |
2019-12-31 |
Novo Nordisk A/S |
Stabilni, dłużej działający współagoniści receptora glp-1/glukagonu do zastosowań medycznych
|
|
JP2014227368A
(ja)
|
2013-05-21 |
2014-12-08 |
国立大学法人帯広畜産大学 |
糖尿病および高血糖状態の処置のためのグルカゴンアナログ
|
|
CN103304660B
(zh)
|
2013-07-12 |
2016-08-10 |
上海昂博生物技术有限公司 |
一种利拉鲁肽的合成方法
|
|
CN103405753B
(zh)
|
2013-08-13 |
2016-05-11 |
上海仁会生物制药股份有限公司 |
稳定的促胰岛素分泌肽水针药物组合物
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
DK3057984T3
(en)
|
2013-10-17 |
2018-10-08 |
Zealand Pharma As |
ACYLED GLUCAGON ANALOGS
|
|
KR102310392B1
(ko)
|
2013-11-06 |
2021-10-13 |
질랜드 파마 에이/에스 |
글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
|
|
TW201609800A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
|
|
TW201609798A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
Ｅｘｅｎｄｉｎ－４胜肽類似物
|
|
TW201609796A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
TW201609795A
(zh)
|
2013-12-13 |
2016-03-16 |
賽諾菲公司 |
作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
CN103665148B
(zh)
|
2013-12-17 |
2016-05-11 |
中国药科大学 |
一种可口服给药的降糖多肽及其制法和用途
|
|
CN103980358B
(zh)
|
2014-01-03 |
2016-08-31 |
杭州阿诺生物医药科技股份有限公司 |
一种制备利拉鲁肽的方法
|
|
CN111658604A
(zh)
|
2014-01-09 |
2020-09-15 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
|
|
CN105960249B
(zh)
|
2014-01-09 |
2021-03-16 |
赛诺菲 |
胰岛素类似物和/或胰岛素衍生物的稳定化药物制剂
|
|
GB201404002D0
(en)
|
2014-03-06 |
2014-04-23 |
Imp Innovations Ltd |
Novel compounds
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
CN104926934B
(zh)
|
2014-09-23 |
2016-11-09 |
蒋先兴 |
胃泌酸调节素类似物
|
|
CN107108713A
(zh)
|
2014-10-10 |
2017-08-29 |
诺和诺德股份有限公司 |
稳定的基于glp‑1的glp‑1/胰高血糖素受体共激动剂
|
|
MX2017005280A
(es)
|
2014-10-24 |
2017-08-15 |
Merck Sharp & Dohme |
Coagonistas de los receptores de glucagon y de glp-1.
|
|
WO2016198604A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
|
|
WO2016198624A1
(en)
|
2015-06-12 |
2016-12-15 |
Sanofi |
Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
|
|
AR105284A1
(es)
|
2015-07-10 |
2017-09-20 |
Sanofi Sa |
Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
|